FDA Considering Biosimilars ‘Guardrails’

US Agency May Take Steps To Prevent Misinformation In Communications

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.

Guardrail_Road
Communications about biosimilars may require some guardrails • Source: Shutterstock

More from Biosimilars

More from Products